IMMUNOHISTOCHEMISTRY, CD 8

The IHC – CD8 (Cluster of Differentiation 8) test is an immunohistochemistry-based diagnostic assay used to detect CD8 protein expression in tissue samples. CD8 is a surface glycoprotein primarily expressed on cytotoxic T lymphocytes, a specialized group of immune cells responsible for identifying and destroying virus-infected and abnormal cells, including cancer cells.

This test is widely used in hematopathology, oncology, and immunology to evaluate T-cell populations, diagnose T-cell lymphomas, and assess immune cell infiltration within tumors. CD8 staining helps pathologists identify cytotoxic T-cell lineage and understand the immune environment surrounding various diseases.

Benefits of the Test

• Helps identify cytotoxic T-cell populations
• Assists in diagnosing T-cell lymphomas
• Supports classification of lymphoid malignancies
• Evaluates immune cell infiltration in tumors
• Improves diagnostic accuracy and treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC CD8 test when there is suspicion of T-cell lymphoid disorders or immune-related abnormalities. It is commonly used in:

• Diagnosis of T-cell lymphoma
• Evaluation of lymphoid malignancies
• Assessment of tumor-infiltrating lymphocytes (TILs)
• Investigation of immune-mediated diseases
• Hematopathology and oncology studies

CD8 is frequently used alongside markers such as CD3, CD4, CD5, CD7, CD20, and Ki-67 to provide a comprehensive immunophenotypic profile of tissue samples.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy, surgical tissue, or bone marrow sample
• No fasting or medication restrictions are needed
• Clinical history and previous pathology reports may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen type and laboratory workflow.

Who Should Take This Test

• Patients with suspected T-cell lymphoma
• Individuals with lymphoid malignancies
• Cases requiring immune cell profiling
• Patients undergoing tumor biopsy evaluation
• Oncology patients needing immunohistochemistry analysis

The IHC CD8 test is an important diagnostic tool in modern pathology and oncology. By identifying cytotoxic T-cell populations and immune responses within tissues, it helps clinicians accurately diagnose disease, classify tumors, and guide treatment decisions.